| Luo(2024)28) | 10d | 1) Hearing improvement2) Tinnitus relief | 1) Hearing improvement 95.0:83.3*2) Tinnitus relief 93.3:80.0* | Improvement of ≥10 ㏈ | 1) Symptom Score of TCM↓*2) sVCAM-1↓*3) NO and SOD↑* | Mild AR (including nausea, vomiting, dizziness, and needle dizziness) |
| Zhang(2024)29) | 6w, 10w | 1) Hearing improvement | 1) Hearing improvement(post treatment) 39.39 : 30.30*2) Hearing improvement (f/u) 54.55:30.30* | Improvement of ≥10 ㏈ | 1) TEQ scores↓*2) CQ-11D health utility values= | Mild AR8cases(including subcutaneous hematomas, pain during needling, fainting) |
| Jiang(2023)30) | 12d | 1) Hearing improvement2) Tinnitus relief | 1) Hearing imrovement 81.81:71.21*2) Tinnitus relief 96.61:83.07* | Improvement of ≥15 ㏈ | 1) THI↓* | No AR reported |
| Tao(2023)31) | 3w | 1) Hearing improvement2) Hearing threshold(PTA) | 1) Hearing imrovement 87.2:74.4*2) Hearing threshold↓* | Improvement of ≥15 ㏈ | 1) THI↓*2) DHI↓*3) Speech Recognition Test Score↓* | No singnificant AR |
| Wei(2022)32) | 4w | 1) Hearing improvement2) Hearing threshold(PTA) | 1) Hearing imrovement 90.0:76.7*2) Hearing threshold↓* | Improvement of ≥15 ㏈ | None | No AR reported |
| Liang(2021)33) | 14d | 1) Hearing improvement2) Tinnitus relief | 1) Hearing improvement 93.33:66.67:73.33*#2) Tinnitus relief 88.89:69.23:58.33*# | Improvement of ≥15 ㏈ | 1) Symptoms(Tinnitus, ear fullness, dizziness) improvement2) Earfullness relief 94.44:93.33:66.67↑*# | No AR reported |
| Jiang(2021)34) | 20d | 1) Hearing improvement2) Hearing threshold(PTA)3) Recovery rate | 1) Hearing imrovement 82.8:83.3:93.5:50.0*2) Hearing threshold↓*3) Recovery rate 20.7:13.3:41.9*:11.5* | Improvement of ≥15 ㏈ | 1) Tinnitus relief : 81.5:75.0:76.0:72.72) Earfullness relief : 88.2:91.7:95.0:57.1*3) Dizziness relief:94.1:87.5:95.2:81.3 | No singnificant AR |
| Sun(2021)35) | 1/3m | 1) Hearing improvement | 1) Hearing improvement 90:00:70:00*/96:00:80:00* | Improvement of ≥15 ㏈ | 1) Tinnitus, Dizziness, Vomiting, Ear fullness ↓*2) Blood viscosity parameters :HCT, WBV, PV, RBC aggregation index, RBC deformability index↓* | No singnificant AR (vasovagal reaction) |
| Zhang(2020)36) | 1/2/4w | 1) Hearing improvement | 1) Hearing improvement↑ F=6.905* | NR | 1) PSQI↓*2) SAS, SDS score↓*3) GQLI, KPS score↑* | No AR reported |
| Sheng(2020)37) | 2/4w | 1) Hearing improvement2) Hearing threshold(PTA) | 1) 69.2:51.32) Hearing threshold↓****(4w) | Improvement of ≥15 ㏈ | 1) THI ↓4w****2) DHI↓4w**** | No AR reported |
| Fan(2020)38) | 4w | 1) Hearing improvement | 1) Hearing improvement 83.9:62.9:68.6*# F=4.326* | NR | None | No AR reported |
| Ju(2020)39) | 14d | 1) Hearing threshold(PTA) | 1) Hearing threshold ↓* | Improvement of ≥15 ㏈ | 1) Relief of accompanying symptoms(ear tightness, distention) CE 97.2:72.2* | No AR reported |
| Lu(2019)40) | 7d | 1) Hearing improvement | 1) Hearing improvement 80.67:68.00* | Improvement of ≥15 ㏈ | 1) Immunological markers (IgA, IgM) ↑* | No AR reported |
| Gao(2019)41) | 4w | 1) Hearing improvement | 1) Hearing improvement 96.36:81.82* | Improvement of ≥15 ㏈ | 1) Blood viscosity parameters :HCT, WBV, PV↓* | No significant AR reported |
| Gong(2018)42) | 2w | 1) ABR | 1) ABR wave latencies (I～Ⅲ, Ⅲ～Ⅴ, I～Ⅴ)↓* | NR | 1) ABR abnormality rate↓* | No AR reported |
| Zhao(2017)43) | 20d | 1) Hearing threshold(PTA)2) Tinnitus relief | 1) Hearing threshold↓*2) Tinnitus relief 92.6:82.1* | NR | 1) ET levels↓*, EPCs↑* | No AR reported |
| Liang(2017)44) | 14d | 1) Hearing improvement2) Tinnitus relief | 1) Hearing improvement 98.04:86.54**2) Tinnitus relief 95.35:65.38** | Improvement of ≥15 ㏈ | 1) Earfullness↓(93.54:87.50)2) Dizziness↓(100.00:90.00) | No AR reported |
| Guo(2016)45) | 1m | 1) Hearing improvement2) Hearing threshold(PTA) | 1) Hearing improvement 97.78:88.89*2) Hearing threshold↓* | Improvement of ≥15 ㏈ | None | No AR reported |
| Yang(2016)46) | 15d | 1) Hearing improvement | 1) Hearing improvement 89.0:84.0* | Improvement of ≥15 ㏈ | None | No significant AR |
| Liu(2015)47) | 14d | 1) Hearing improvement2) Hearing threshold(PTA) | 1) Hearing improvement 93.33:76.67*2) Hearing threshold↓* | Improvement of ≥15 ㏈ | None | No AR reported |
| Huang(2014)48) | 20d | 1) Hearing improvement | 1) Hearing improvement 88.14:73:58* | Improvement of ≥15 ㏈ | 1) Tinnitus relief↑2) Dizziness relief↑ | No AR reported |
| Liang(2014)49) | 1/2/4w | 1) Hearing improvement | 1) Hearing improvement 86.7:63.3*/96.7:70.0*/96.7:76.7* | Improvement of ≥15 ㏈ | None | No AR reported |
| Xu(2013)50) | 15d | 1) Hearing improvement | 1) Hearing improvement 86.7:78.1* | Improvement of ≥15 ㏈ | None | No AR reported |
| Luo(2012)51) | 6w | 1) Hearing improvement | 1) Hearing improvement 89.2:62.5:53.4**# | Improvement of ≥15 ㏈ | None | No significant AR (Hematoma) |
| Qiu(2012)52) | 20d | 1) Hearing improvement2) Hearing threshold(PTA) | 1) Hearing improvement 50.0:55.92) 250 ㎐/500 ㎐/1 ㎑ hearing threshold↓3) 2 ㎑ hearingthreshold↓*4) 4 ㎑ hearing threshold= | Improvement of ≥15 ㏈ | None | No significant AR1)ALT,BUN,CR↑2)RBC,WBC,PLT↓ |
| Chen(2011)53) | 10d | 1) Hearing improvement | 1) Hearing improvement 70.0:60.0* | Improvement of ≥15 ㏈ | 1) Tinnitus relief↑*2) Dizziness relief↑* | No AR reported |
| Wu(2010)54) | NR | 1) Hearing improvement | 1) Hearing improvement 95.65:54.60* | Improvement of ≥15 ㏈ | 1) The severity of hearing loss and treatment efficacy * | No AR reported |
| Luo(2009)55) | 10d | 1) Hearing improvement | 1) Hearing improvement 86.7:60.0* | Improvement of ≥15 ㏈ | 1) Whole blood viscosity ↓*2) HCT↓3) PV↓*4) Fibrinogen↓* | No AR reported |